title: [Radionuclide screening in endocrinology].
abstract: The study provides an overview of current possibilities for use of nuclear medicine methods in endocrine diagnostics and therapy. Somatostatin receptor analogue is applied to the hypothalamus-hypophysis system, analogue medium to is used, in thyroid diagnostics, besides the determined tumour markers, tenchecium-labelled MIBI radioiodine 131 is used to determine and monitor carcinomas. Recently, rhTSH before starting thyroid carcinoma treatment is used. Neuroendocrinology tumours are suspected through 123I-MIBG; when scintigraphy is positive, therapeutic 131I-MIBG can be administrated. In diagnostics of the pituitary gland, two-step scintigraphy of MIBI is preferably used rather than subtraction methods. In patients with late or not significantly differenciated malignant tumours, positrone emission tomography is of benefit.
authors.affiliation: Klinika nukleární medicíny a endokrinologie 2. lékarské fakulty UK a FN Motol, Praha. petr.vlcek@lfmotol.cz
authors.forename: P
authors.initials: P
authors.lastname: Vlcek
authors.forename: K
authors.initials: K
authors.lastname: Michalová
authors.forename: K
authors.initials: K
authors.lastname: Táborská
authors.forename: P
authors.initials: P
authors.lastname: Sýkorová
mesh_terms: D006801:Humans; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013959:Thyroid Diseases / Q000000981:diagnostic imaging*
chemical_list: D019275:Radiopharmaceuticals